



## ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2020 - GENERELL INFORMASJON

### Enheten

Organisasjonsnummer:	922 221 529
Organisasjonsform:	Aksjeselskap
Foretaksnavn:	CELLTRION HEALTHCARE NORWAY AS
Forretningsadresse:	C/O Spaces Aker Brygge Fjordalléen 16 0250 OSLO

### Regnskapsår

Årsregnskapets periode:	01.01.2020 - 31.12.2020
-------------------------	-------------------------

### Konsern

Morselskap i konsern:	Nei
-----------------------	-----

### Regnskapsregler

Regler for små foretak benyttet:	Ja
Benyttet ved utarbeidelsen av årsregnskapet til selskapet:	Regnskapslovens alminnelige regler

### Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet:	Hangi Lee
Dato for fastsettelse av årsregnskapet:	17.08.2021

### Grunnlag for avgivelse

År 2020: Årsregnskapet er elektronisk innlevert  
År 2019: Tall er hentet fra elektronisk innlevert årsregnskap fra 2020

*Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.*

Brønnøysundregistrene, 31.08.2022



## Resultatregnskap

Beløp i: NOK	Note	2020	2019
<b>RESULTATREGNSKAP</b>			
<b>Inntekter</b>			
Revenue		453 459	17 554
<b>Sum inntekter</b>		<b>453 459</b>	<b>17 554</b>
<b>Kostnader</b>			
Cost of materials		13 755	15 674
Personnel expenses	2	286 119	
Other operating expenses	2	105 000	165 719
<b>Sum kostnader</b>		<b>404 874</b>	<b>181 393</b>
<b>Driftsresultat</b>		<b>48 585</b>	<b>-163 839</b>
<b>Finansinntekter og finanskostnader</b>			
Other financial income		566	
<b>Sum finansinntekter</b>		<b>566</b>	
Other financial expenses			
<b>Netto finans</b>		<b>566</b>	
<b>Ordinært resultat før skattekostnad</b>		<b>49 151</b>	<b>-163 839</b>
Tax on ordinary result	5		
<b>Ordinært resultat etter skattekostnad</b>		<b>49 151</b>	<b>-163 839</b>
<b>Årsresultat</b>	3	<b>49 151</b>	<b>-163 839</b>
<b>Årsresultat etter minoritetsinteresser</b>		<b>49 151</b>	<b>-163 839</b>
<b>Totalresultat</b>		<b>49 151</b>	<b>-163 839</b>
<b>Overføringer og disponeringer</b>			
Udekket tap		49 151	-163 839
<b>Sum overføringer og disponeringer</b>		<b>49 151</b>	<b>-163 839</b>



### Balanse

Beløp i: NOK	Note	2020	2019
<b>BALANSE - EIENDELER</b>			
<b>Anleggsmidler</b>			
<b>Immaterielle eiendeler</b>			
Utsatt skattefordel	5		
Other long-term receivables	7		
<b>Sum anleggsmidler</b>		<b>0</b>	<b>0</b>
<b>Omløpsmidler</b>			
<b>Varer</b>			
<b>Fordringer</b>			
Accounts receivables	6, 7	92 857	17 554
Other short-term receivables	7	121 250	129 562
<b>Sum fordringer</b>		<b>214 107</b>	<b>147 116</b>
<b>Bankinnskudd, kontanter og lignende</b>			
Cash and bank deposits	4	73 719	123 122
<b>Sum bankinnskudd, kontanter og lignende</b>		<b>73 719</b>	<b>123 122</b>
<b>Sum omløpsmidler</b>		<b>287 825</b>	<b>270 238</b>
<b>SUM EIENDELER</b>		<b>287 825</b>	<b>270 238</b>
<b>BALANSE - EGENKAPITAL OG GJELD</b>			
<b>Egenkapital</b>			
<b>Innskutt egenkapital</b>			
Share capital	1	30 000	30 000
<b>Sum innskutt egenkapital</b>		<b>30 000</b>	<b>30 000</b>
<b>Opptjent egenkapital</b>			
Other equity	8		
Udekket tap		114 689	163 839
<b>Sum opptjent egenkapital</b>		<b>-114 689</b>	<b>-163 839</b>



## Balanse

Beløp i: NOK	Note	2020	2019
<b>Sum egenkapital</b>	3	<b>-84 689</b>	<b>-133 839</b>
<b>Gjeld</b>			
<b>Langsiktig gjeld</b>			
Utsatt skatt	5		
<b>Annen langsiktig gjeld</b>			
Langsiktig konserngjeld	7		
<b>Sum langsiktig gjeld</b>		<b>0</b>	<b>0</b>
<b>Kortsiktig gjeld</b>			
Leverandørgjeld	7	59 316	104 077
Tax payable	5		
Kortsiktig konserngjeld		300 000	300 000
Other current debt	7	13 197	
<b>Sum kortsiktig gjeld</b>		<b>372 514</b>	<b>404 077</b>
<b>Sum gjeld</b>		<b>372 514</b>	<b>404 077</b>
<b>SUM EGENKAPITAL OG GJELD</b>		<b>287 825</b>	<b>270 238</b>



## Brønnøysundregistrene

### ÅRSREGNSKAP FOR REGNSKAPSÅRET 2020 - GENERELL INFORMASJON

Journalnummer: 2021 776416

#### Enheten

Organisasjonsnummer: 922 221 529  
Organisasjonsform: Aksjeselskap  
Foretaksnavn: CELLTRION HEALTHCARE NORWAY AS  
Forretningsadresse: 2nd floor  
Filipstad brygge 1  
0252 OSLO

#### Regnskapsår

Årsregnskapets periode: 01.01.2020 - 31.12.2020

#### Konsern

Morselskap i konsern: Nei

#### Regnskapsregler

Regler for små foretak benyttet: Ja  
Benyttet ved utarbeidelsen av  
årsregnskapet til selskapet: Regnskapslovens alminnelige regler  
Har utarbeidet 'land-for-land' rapport: Ja

#### Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Hangi Lee  
Dato for fastsettelse av årsregnskapet: 17.08.2021

#### Revisjon

Selskapet har besluttet at årsregnskapet  
ikke skal revideres: Ja  
Årsregnskapet er utarbeidet av ekstern  
autorisert regnskapsfører: Ja  
Ekstern autorisert regnskapsfører har i  
løpet av regnskapsåret bistått ved den  
løpende regnskapsføringen eller utført  
andre tjenester for selskapet enn å  
utarbeide årsregnskapet: Ja

#### Grunnlag for avgivelse

År 2020: Årsregnskap er elektronisk innlevert.  
År 2019: Tall er hentet fra elektronisk innlevert årsregnskap fra 2020.

*Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.*

Brønnøysundregistrene, 21.09.2021

---

Brønnøysundregistrene  
Postadresse: Postboks 900, 8910 Brønnøysund  
Telefon: 75 00 75 00  
E-post: firmapost@brreg.no Internett: www.brreg.no  
Organisasjonsnummer: 974 760 673



Organisasjonsnr: 922 221 529  
CELLTRION HEALTHCARE NORWAY AS

## RESULTATREGNSKAP

<b>Beløp i: NOK</b>	<b>Note</b>	<b>2020</b>	<b>2019</b>
<b>RESULTATREGNSKAP</b>			
<b>Inntekter</b>			
Revenue		453 459	17 554
<b>Sum inntekter</b>		<b>453 459</b>	<b>17 554</b>
<b>Kostnader</b>			
Cost of materials		13 755	15 674
Personnel expenses	2	286 119	
Other operating expenses	2	105 000	165 719
<b>Sum kostnader</b>		<b>404 874</b>	<b>181 393</b>
<b>Driftsresultat</b>		<b>48 585</b>	<b>-163 839</b>
<b>Finansinntekter og finanskostnader</b>			
Other financial income		566	
<b>Sum finansinntekter</b>		<b>566</b>	
Other financial expenses			
<b>Netto finans</b>		<b>566</b>	
<b>Ordinært resultat før skattekostnad</b>		<b>49 151</b>	<b>-163 839</b>
Tax on ordinary result	5		
<b>Ordinært resultat etter skattekostnad</b>		<b>49 151</b>	<b>-163 839</b>
<b>Årsresultat</b>	3	<b>49 151</b>	<b>-163 839</b>
<b>Årsresultat etter minoritetsinteresser</b>		<b>49 151</b>	<b>-163 839</b>
<b>Totalresultat</b>		<b>49 151</b>	<b>-163 839</b>
<b>Overføringer og disponeringer</b>			
Udekket tap		49 151	-163 839
<b>Sum overføringer og disponeringer</b>		<b>49 151</b>	<b>-163 839</b>



Organisasjonsnr: 922 221 529  
CELLTRION HEALTHCARE NORWAY AS

## BALANSE

**Beløp i: NOK** **Note** **2020** **2019**

### BALANSE - EIENDELER

#### Anleggsmidler

##### Immaterielle eiendeler

Utsatt skattefordel 5

Other long-term receivables 7

**Sum anleggsmidler** 0 0

#### Omløpsmidler

##### Varer

#### Fordringer

Accounts receivables 6, 7 92 857 17 554

Other short-term receivables 7 121 250 129 562

**Sum fordringer** 214 107 147 116

#### Bankinnskudd, kontanter

##### og lignende

Cash and bank deposits 4 73 719 123 122

**Sum bankinnskudd,**

**kontanter og lignende** 73 719 123 122

**Sum omløpsmidler** 287 825 270 238

**SUM EIENDELER** 287 825 270 238

### BALANSE - EGENKAPITAL OG GJELD

#### Egenkapital

##### Innskutt egenkapital

Share capital 1 30 000 30 000

**Sum innskutt egenkapital** 30 000 30 000

##### Opptjent egenkapital

Other equity 8

Udekket tap 114 689 163 839

**Sum opptjent egenkapital** -114 689 -163 839

**Sum egenkapital** 3 -84 689 -133 839

#### Gjeld

##### Langsiktig gjeld

Utsatt skatt 5

##### Annen langsiktig gjeld

Langsiktig konserngjeld 7



<b>Sum langsiktig gjeld</b>		<b>0</b>	<b>0</b>
<b>Kortsiktig gjeld</b>			
Leverandørgjeld	7	59 316	104 077
Tax payable	5		
Kortsiktig konserngjeld		300 000	300 000
Other current debt	7	13 197	
<b>Sum kortsiktig gjeld</b>		<b>372 514</b>	<b>404 077</b>
<b>Sum gjeld</b>		<b>372 514</b>	<b>404 077</b>
<b>SUM EGENKAPITAL OG GJELD</b>		<b>287 825</b>	<b>270 238</b>



Organisasjonsnr: 922 221 529  
CELLTRION HEALTHCARE NORWAY AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note

Antall årsverk i regnskapsåret

Virksomheten har hatt følgende antall årsverk:  
0.00



Our date 30.04.2020	Your date 06.04.2020	Case officer Lars Waalorp
800 80 000 skatteetaten.no	Your reference AR368600843	Telephone +4732212244
Org. nr. 974761076	Our reference 2020/5339261	Postal address Postboks 9200 Grønland 0134 OSLO

CELLTRION HEALTHCARE NORWAY AS  
Cort Adellers gate 16  
0254 OSLO

*Callers from abroad, please call +47 22 07 70 00*

Att. Weronika Bortzmeyer, BDO AS

## Permission to prepare the annual accounts and directors' report in English language for Celltrion Healthcare Norway AS, org. no 922 221 529

With reference to your letter received 6 April 2020 with respect to the above matter regarding Celltrion Healthcare Norway AS.

Based on a total evaluation, the view of the tax office is that Celltrion Healthcare Norway AS may make the directors' report and annual accounts in English language according to the Norwegian Accounting Act § 3-4 third paragraph. The exemption requires that the information the decision is based on, does not change significantly.

A copy of this letter must be sent to the Register of Company Accounts in Brønnøysund together with the financial statements. It is incumbent on the company to document by this letter that the permit is granted.

### Background

Celltrion Healthcare Norway AS is a private limited company 100 % owned by a foreign company. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion - a biopharmaceutical company headquartered in South Korea. The key players and partners in the industry speak and use English. The company uses English as the working language, alongside Korean. The chairman of the board is not Norwegian.

### Condition for the permission

According to the Norwegian Accounting Act § 3-4, third paragraph shall "the directors' report and annual accounts ... be in Norwegian. The Ministry can in an individual decision decide that the directors' report and/or annual accounts may be in another language".

Ot. prp. nr. 42 (1997-1998) About Act about annual accounts etc., says the following about the purpose of the Accounting Act, refer section 1.1:

"The aim of the Government with respect to the Accounting Act is that it shall contribute towards providing informative accounts for different users of accounts. The users of accounts include investors and creditors, which provide capital for the companies. Other groups include those who have an interest in knowing how the companies are operated, for example employees and the local community. The information to the capital market is an important basis for the correct pricing of financial instruments. The



correct pricing of stocks is an important factor in securing the best possible allocation of resources in the economy. High quality accounts will also make it more difficult for market participants to obtain speculative gains as a result of non-publicly available information.”

One of the main goals of the Accounting Act is to contribute to “informative accounts for different users of accounts”. The users of the accounts will include investors, creditors, employees and the local community.

Hence, it is the view of the Ministry that it is crucial that the question of dispensation from the general rule that the annual accounts and/or directors’ report should be prepared in Norwegian, not in any significant way deviate from the consideration of users of the accounts.


As mentioned above it is particularly the consideration of the users of the account information, which has to be taken into consideration when considering the application for permission. In this assessment, the tax office has emphasized that the company is a subsidiary of a foreign company. Furthermore, all key players and partners in this industry understand and use English.

Please state “our reference” (see above) in all written communication with the Norwegian Tax Authorities.

Yours sincerely,


Lars Waalorp  
Senior Adviser  
Customer Interaction Division, Customer Service  
The Norwegian Tax Administration

*This document has been electronically approved and therefore has no handwritten signatures.*



**Annual Report 2020**  
**Celltrion Healthcare Norway AS**

Revenue statement  
Balance sheet  
Notes to the Accounts



Org.no.: 922 221 529



## REVENUE STATEMENT

### CELLTRION HEALTHCARE NORWAY AS

OPERATING INCOME AND OPERATING EXPENSES	Note	2020	2019
Revenue		453 459	17 554
<b>Total operating income</b>		<b>453 459</b>	<b>17 554</b>
Cost of materials		13 755	15 674
Personnel expenses	2	286 119	0
Other operating expenses	2	105 000	165 719
<b>Total operating expenses</b>		<b>404 874</b>	<b>181 393</b>
<b>Operating profit</b>		<b>48 585</b>	<b>-163 839</b>
Other financial income		566	0
<b>Net financial items</b>		<b>566</b>	<b>0</b>
Operating result before tax		49 151	-163 839
<b>Ordinary result after tax</b>		<b>49 151</b>	<b>-163 839</b>
<b>Annual net profit</b>	<b>3</b>	<b>49 151</b>	<b>-163 839</b>
<b>BROUGHT FORWARD</b>			
Loss brought forward		-49 151	163 839
<b>Net brought forward</b>		<b>49 151</b>	<b>-163 839</b>



## BALANCE SHEET

### CELLTRION HEALTHCARE NORWAY AS

	Note	2020	2019
<b>CURRENT ASSETS</b>			
<b>DEBTORS</b>			
Accounts receivables	6, 7	92 857	17 554
Other short-term receivables	7	121 250	129 562
<b>Total receivables</b>		<b>214 107</b>	<b>147 116</b>
Cash and bank deposits	4	73 719	123 122
<b>Total current assets</b>		<b>287 825</b>	<b>270 238</b>
<b>Total assets</b>		<b>287 825</b>	<b>270 238</b>




## BALANCE SHEET

### CELLTRION HEALTHCARE NORWAY AS

EQUITY AND LIABILITIES	Note	2020	2019
<b>EQUITY</b>			
<b>PAID-UP EQUITY</b>			
Share capital	1	30 000	30 000
<b>Total paid-up equity</b>		<b>30 000</b>	<b>30 000</b>
<b>RETAINED EARNINGS</b>			
Uncovered loss		-114 689	-163 839
<b>Total retained earnings</b>		<b>-114 689</b>	<b>-163 839</b>
<b>Total equity</b>	<b>3</b>	<b>-84 689</b>	<b>-133 839</b>
<b>LIABILITIES</b>			
<b>CURRENT DEBT</b>			
Trade creditors	7	59 316	104 077
Liabilities to group companies		300 000	300 000
Other current debt	7	13 197	0
<b>Total current debt</b>		<b>372 514</b>	<b>404 077</b>
<b>Total liabilities</b>		<b>372 514</b>	<b>404 077</b>
<b>Total equity and liabilities</b>		<b>287 825</b>	<b>270 238</b>

The board of Celltrion Healthcare Norway AS

  
Hangi Lee  
chairman of the board  
2021.08.10

  
Hans Gustav Clemetsen  
member of the board  
2021.08.09



## **Accounting principles**

The annual accounts have been prepared in conformity with the Accounting Act and NRS 8 - Good accounting practice for small companies.

## **OPERATING REVENUES**

Income from the sale of the goods is recognised on the date of delivery. Services are posted to income as they are delivered.

## **TAX**

The tax charge in the profit and loss account consists of tax payable for the period and the change in deferred tax. Deferred tax is calculated at the tax rate at 22 % on the basis of tax-reducing and tax-increasing temporary differences that exist between accounting and tax values, and the tax loss carried forward at the end of the accounting year. Tax-increasing and tax-reducing temporary differences that reverse or may reverse in the same period are set off and entered net.

## **CLASSIFICATION AND VALUATION OF CURRENT ASSETS**

Current assets and short-term liabilities normally include items that fall due for payment within one year of the balance sheet date, as well as items that relate to the stock cycle. Current assets are valued at the lower of acquisition cost and fair value.

## **RECEIVABLES**

Receivables from customers and other receivables are entered at par value after deducting a provision for expected losses. The provision for losses is made on the basis of an individual assessment of the respective receivables.



## Note 1 Total shares, shareholders etc

Share capital	Number	Par value	Capitalised
Ordinary shares	30.000	1	30.000

All shares carry the same rights in the company.

Celltrion Healthcare Norway AS had 1 shareholder as at 31.12.2020. Celltrion Healthcare Hungary Kft owns 100 % of the shares in the company.

## Note 2 Number of employees, remuneration, loans to employees etc.

Number of man-years employed in the accounting year: 0

### Remuneration to leading personnel

	Salaries	Pension costs	Other remuneration
Chief executive	0	0	0
Board	0	0	97.000

### Auditor

The company is not subject to audit requirement.

## Note 3 Equity capital

	Share capital	Share premium	Other paid-in equity capital	Other equity capital	Total equity capital
As of 22.11.2019		0	0	-163 839	-163 839
Changes posted against equity	30 000			0	30 000
<b>As of 01.01.2020</b>	<b>30 000</b>	<b>0</b>	<b>0</b>	<b>-163 839</b>	<b>-133 839</b>
Result for the year				49 151	49 151
Dividend				0	0
<b>As of 31.12.2020</b>	<b>30 000</b>	<b>0</b>	<b>0</b>	<b>-114 689</b>	<b>-84 689</b>

## Note 4 Bank deposits

The company has no employees and is not subject to keep tax deduction account.



**Note 5 Tax**

	<b>2020</b>
Tax payable	0
Change in deferred tax	0
<b>Total tax charge</b>	<b>0</b>
<b>Calculation of the tax base for the year:</b>	<b>2020</b>
Result before tax	49 151
Permanent differences	0
Change in temporary differences	0
<b>The year's tax base</b>	<b>49 151</b>

**Note 6 Customer receivables**

	<b>2020</b>
Customer receivables at par value	92 857
Provision for losses	0
<b>Book value of customer receivables 31.12</b>	<b>92 857</b>
	<b>2020</b>
Customers receivable with the parent company, Celltrion Healthcare Hungary Kft	92 857

**Note 7 Intercompany items between companies in the same group etc.**

	<b>Customer receivables</b>	<b>Other receivables</b>
	<b>2020</b>	<b>2020</b>
Companies in the same group	92 857	0
<b>Total</b>	<b>92 857</b>	<b>0</b>
	<b>Debt to suppliers</b>	<b>Other long-term liabilities</b>
	<b>2020</b>	<b>2020</b>
Companies in the same group	-300 000	0
<b>Total</b>	<b>-300 000</b>	<b>0</b>



**Note 8 Going concern**

Celltrion Healthcare Norway AS has changed to a net gain for 2020 but still has a negative shareholder equity as of 31.12.2020. Celltrion Healthcare Norway AS is still in its market research phase and expects neutral ongoing operations in the near future. Further, the board of Celltrion Healthcare Norway AS has passed a decision on share capital increase which will be carried out in 2021. Based on these measurements, Celltrion Healthcare Norway AS does not consider to involve a risk of loss for the creditors, and the board considers that the going concern conditions are satisfied.

The Covid-19 outbreak in 2020 have no negative effects on company's business.